Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Roivant Sciences Ltd

Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its prospects.

StockNews.com · Nov 21, 2023

3 Healthcare Stocks Wall Street Expects to Soar Nearly 200%

Substantial investments in R&D and growing demand for advanced drugs to treat chronic diseases should drive the healthcare industry’s growth. Moreover, amid the economy's uncertainties, the inelastic demand is expected to keep the sector resilient. Given this backdrop, Wall Street analysts expect healthcare stocks Ginkgo Bioworks (DNA), Zai Lab (ZLAB),…

StockNews.com · Aug 25, 2022

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

Benzinga · Jun 28, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate

Roivant Sciences Ltd's (NASDAQ: ROIV) subsidiary Dermavant Sciences announced results from Phase 3 PSOARING 3 long-term extension study of tapinarof cream 1% for plaque psoriasis in adults.

Benzinga · Mar 25, 2022

Coverage From

Organisations

Ginkgo Bioworks Holdings Inc

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.